Targeting RAS Signaling Pathways: Molecular Regulation, FDA‐Approved Inhibitors, Clinical Advances, and Patent Innovations
Drug Development Research · 2026-12 · 87 (8)
DOI: 10.1002/ddr.70410 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 18.11.2026. Verfasst von Ajad Chauhan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, Punjab, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, ras Proteins, Neoplasms. Die Arbeit nennt 86 Literaturangaben.
Abstract (Originalsprache)
RAS gene mutations play a major role in the development and progression of cancer. According to recent data, mutations in the RAS gene are responsible for nearly 30% of all cancer cases worldwide. Among these, KRAS mutations account for more than 85% of all RAS mutations and are particularly prevalent in aggressive malignancies, including colorectal cancer (CRC), non‐small‐cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC). In this manuscript, we provide a detailed discussion of the RAS signaling cascades and their regulatory mechanisms. The catalytic region of RAS proteins, which comprises the P‐loop, Switch I and Switch II regions, and RAS–effector interaction surfaces, exhibits a high degree of structural conservation across the different RAS isoforms. Sotorasib was the first covalent KRAS inhibitor to receive regulatory approval and acts by irreversibly binding to the cysteine residue at position 12 (Cys12). In this manuscript, we discuss in detail targeted RAS inhibitors, including adagrasib (MRTX849), fulzerasib (IBI351), garsorasib (D‐1553), glecirasib (JAB‐21822), and divarasib (GDC‐6036). Finally, we focus on recent advances in RAS inhibitor patents from 2019 to the present, with particular emphasis on thiazole, benzothiazole, quinazoline, and other emerging chemical scaffolds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, Punjab, India.
- Department of Pharmaceutical Sciences, School of Health Sciences and Technology, University of Petroleum and Energy Studies (UPES), Dehradun, Uttarakhand, India.
- Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, Uttar Pradesh, India.
- Department of Chemistry, College of Science, University College of Taraba, Taif University, Taif, Saudi Arabia.
ORCID-Profile: Ajad Chauhan, Vineet Prajapati, Ankit Kumar Singh, Adarsh Kumar, Rakesh Mishra, Amita Verma, Magda H Abdellattif, Pradeep Kumar
Zitieren
APA
Chauhan, A., Prajapati, V., Singh, A. K., Kalsi, A. S., Kumar, A., Mishra, R., Verma, A., Abdellattif, M. H., & Kumar, P. (2026). Targeting RAS Signaling Pathways: Molecular Regulation, FDA‐Approved Inhibitors, Clinical Advances, and Patent Innovations. Drug Development Research, 87(8). https://doi.org/10.1002/ddr.70410
Vancouver
Chauhan A, Prajapati V, Singh AK, Kalsi AS, Kumar A, Mishra R, et al. Targeting RAS Signaling Pathways: Molecular Regulation, FDA‐Approved Inhibitors, Clinical Advances, and Patent Innovations. Drug Development Research. 2026;87(8). doi:10.1002/ddr.70410
BibTeX
@article{Chauhan2026,
author = {Chauhan, Ajad and Prajapati, Vineet and Singh, Ankit Kumar and Kalsi, Amandeep Singh and Kumar, Adarsh and Mishra, Rakesh and Verma, Amita and Abdellattif, Magda H and Kumar, Pradeep},
title = {Targeting RAS Signaling Pathways: Molecular Regulation, FDA‐Approved Inhibitors, Clinical Advances, and Patent Innovations},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {8},
doi = {10.1002/ddr.70410}
}
EUVIMED